Nav1.7 antisense oligonucleotide - Q-State Biosciences
Alternative Names: Nav1.7 ASO - Q-State BiosciencesLatest Information Update: 23 Jul 2021
Price :
$50 *
At a glance
- Originator Q-State Biosciences
- Class Antisense oligonucleotides; Non-opioid analgesics
- Mechanism of Action NAV1.7 voltage gated sodium channel expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Pain
Most Recent Events
- 23 Jul 2021 Nav1.7 antisense oligonucleotide - Q-State Biosciences is available for licensing as of 23 Jul 2021. (https://www.qstatebio.com/partnerships)
- 20 Jul 2021 Early research in Pain in USA (Parenteral) (Q-State Biosciences pipeline, July 2021)
- 06 Jan 2020 Q-State Biosciences receives SBIR grant from National Institutes of Health for development of ASO therapeutics for cancer pain